

PHARMACEUTICAL COMPOSITIONS COMPRISING MICELLES COMPRISING LIPOPHILIC GLUCOCORTICOSTEROID AND ONLY ONE SURFACTANT

FIELD OF INVENTION

5 The present invention relates to a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant. The invention further relates to a process for the preparation of the pharmaceutical composition and use of the pharmaceutical composition for the manufacture of a medicament for treating allergic and/or inflammatory diseases in the respiratory tract or for treating intestinal diseases and methods for
10 treatment of the diseases in a mammal, including man.

BACKGROUND OF THE INVENTION

15 Rhinitis and asthma are today effectively treated by the use of glucocorticosteroids such as e.g. mometasone furoate, budesonide, and fluticasone propionate. Patent applications that can be mentioned in this context are WO 92/13873 and WO 96/19199 both to Astra AB of Sweden.

20 Well-known methods of administering the glucocorticosteroids are by oral and nasal inhalation. The glucocorticosteroid compositions are used in the form of powders in dry powder inhalers, as solutions or suspensions in pressurized metered dose inhalers (pMDIs). A suspension in water is a user-friendly form of administration as the solution is easily accepted by the mucosa. However, in a water suspension the glucocorticosteroid crystals
25 are in contact with the water which can affect the stability of the glucocorticosteroid. A glucocorticosteroid ester may be chemically degraded for example by ester hydrolysis when using such a compound. Further, the compositions in the form of suspensions may be less stable than solutions e.g. due to sedimentation or precipitation. It is also easier to administer a solution accurately in comparison with a suspension.



166166



G00002

US 4,994,439 to California Biotechnology discloses aqueous compositions for trans-mucosal membrane administration of protein or peptide drugs wherein the compositions comprise the drug in mixtures with at least one bile salt or fusidate or a derivative thereof and at least one non-ionic detergent of the formula $RO(CH_2R'CH_2O)_nR$, wherein one R is H and the other R represents the radical of a saturated or unsaturated cyclic or acyclic organic alcohol of 6-40 carbons. The use of a mixture of carrier components results in the formation of mixed micelles, exhibiting transport efficiencies across mucous membranes comparable to or better than those achieved using bile salts/fusidates alone. Detergents on their own are said to be poor absorption promoters.

EP 0179583 A1 to Merck & Co. Inc. discloses a system for enhancing the water dissolution rate and solubility of poorly soluble drugs. The compositions of EP 0179583 A1 involve combining the poorly water-soluble drug with the surfactant in appropriate ratios and by an appropriate method that results in the formation of an anhydrous product. The examples are directed to anhydrous compositions of the antiparasitic agents ivermectin or abamectin and a surfactant.

It is an object of the present invention to provide a stable aqueous solution of a lipophilic glucocorticosteroid for use as a medicament, especially for treating allergic and/or inflammatory diseases in the respiratory tract and also for treating intestinal diseases such as inflammatory bowel diseases (IBD), ulcerative colitis and Crohn's disease.

It is a further object of the invention to provide a process for the preparation of such a stable solution.

SUMMARY OF THE INVENTION

According to the invention there is provided a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant.

According to a preferred embodiment the composition comprises one and only one non-ionic surfactant.

According to another preferred embodiment the composition is used for treating allergic and/or inflammatory diseases in the respiratory tract.

According to yet another preferred embodiment the composition is used for treating intestinal diseases.

According to a further aspect of the invention a process for the preparation of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant, the process comprising the steps of:

- a) dissolving the glucocorticosteroid in the surfactant;
- b) adding an aqueous medium to the solution from step a) and stirring the solution.

According to yet another aspect of the invention use of a composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant, for the manufacture of a medicament for treating allergic and inflammatory diseases in the respiratory tract is obtained.

According to a further aspect of the invention use of a composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and

one and only one pharmaceutically acceptable surfactant for the manufacture of a medication for treating intestinal diseases is obtained.

Another aspect of the invention is a method for treatment of allergic and/or inflammatory diseases in the respiratory tract of a mammal, including man. The method is characterized by administration to the mammal in need of such treatment of an therapeutically effective amount of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant.

10

A last aspect of the invention is a method for treatment of intestinal diseases in a mammal, including man. The method is characterized by administration to the mammal in need of such treatment of an therapeutically effective amount of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant.

15

DETAILED DESCRIPTION OF THE INVENTION

According to the present invention it was found that lipophilic glucocorticosteroids and their esters can be incorporated in micelles formed by a surfactant, especially a non-ionic surfactant, in an aqueous medium. According to "Pharmaceutical Dosage Forms; Disperse Systems", vol.1, p.315 ff (1988) ed. by H.A. Lieberman et al, micelles are molecular aggregates formed in the solution of a surfactant. Surfactants in a dilute aqueous solution exist primarily as monomers, but at higher concentrations a number of surfactant molecules aggregate to form micelles. Thereby a stable formulation is obtained in which the lipophilic glucocorticosteroid/glucocorticosteroid ester is protected and is possible to be absorbed.

20

25

The micelles will act as non-aqueous reservoirs for the lipophilic glucocorticosteroid and will positively affect the pharmacokinetic and deposition of the glucocorticosteroid molecule. The glucocorticosteroid will also be more easy to dose accurately as well as for

30

the patient to administer accurately. For further information of the expression "lipophilic" reference can be made to the above mentioned reference where on p. 155 it is stated that "lipophilic drugs may be wetted by oils and semipolar liquids."

5 The problem with preparation of compositions comprising the lipophilic glucocorticosteroids used in the invention in an aqueous medium is that they are very difficult to dissolve in water and then to obtain a stable composition. It was found in the present invention that by dissolving the lipophilic glucocorticosteroid in a surfactant, preferably a non-ionic surfactant, stable compositions can be obtained with the glucocorticosteroid in
10 micellar form.

The inventor of the present invention, has further found that use of the stable compositions comprising e.g. rofleponide palmitate incorporated in micelles formed by a surfactant, causes less irritation in the lung after oral inhalation by human patients, than is experienced
15 after oral inhalation of the same surfactant on its own.

The present compositions comprise one and only one surfactant. The surfactant used in the present compositions can be non-ionic, zwitterionic, anionic or cationic. It is, however, preferred, to use a non-ionic surfactant, since this normally reduces the risk of side-effects
20 after administration. Examples of non-ionic, zwitterionic, anionic or cationic surfactants which may be used in the present invention can be found in Wade and Weller, Handbook of Pharmaceutical Excipients, 1994, The Pharmaceutical Press, London.

The non-ionic surfactants used according to the present invention are suitably selected from
25 poloxamers, e.g. poloxamer 188; polyoxyethylene alkyl ethers, e.g. poloxyl 10 stearyl ether, poloxyl 20 stearyl ether; polyoxyethylene stearates, e.g. polyoxyl 8 stearate, poloxyl 12 stearate; polyoxyethyleneglycol hydroxystearates, e.g. polyoxyethyleneglycol 12-hydroxystearates, and polyoxyethylene sorbitan fatty acid esters. A preferred group of non-ionic surfactants is polyoxyethylene sorbitan fatty acid esters, e.g. polyoxyethylene 20
30 sorbitan monolaurate, monopalmitate, monostearate or monooleate also known as poly-

sorbate 20, polysorbate 40, polysorbate 60 and polysorbate 80, respectively. Examples of suitable commercial polysorbates are Tween[™] 20, Tween[™] 40, Tween[™] 60 and Tween[™] 80.

A further preferred group of non-ionic surfactants is polyoxyethyleneglycol 12-hydroxystearates and an especially preferred compound is polyoxyethyleneglycol 660 12-hydroxystearate.

In the present invention, lipophilic glucocorticosteroids relate to lipophilic glucocorticosteroids *per se*, as well as their pharmaceutically acceptable solvates, esters, acetals and salts, and solvates of any of these.

10

Examples of glucocorticosteroids which may be used in the present invention include betamethasone, fluticasone (e.g. as propionate), budesonide, tipredane, dexamethasone, beclomethasone (e.g. as dipropionate), prednisolone, fluocinolone (e.g. as acetonide), triamcinolone (e.g. as acetonide), mometasone (e.g. as furoate), rofleponide (e.g. as palmitate), flumethasone, flunisolide, ciclesonide, deflazacort, cortivazol, 16 α ,17 α -butylidenedioxy-6 α ,9 α -difluoro-11 β ,21-dihydroxy-pregna-1,4-diene-3,20-dione; 6 α ,9 α -difluoro-11 β -hydroxy-16 α ,17 α -butylidenedioxy-17 β -methylthio-androsta-4-ene-3-one; 16 α ,17 α -butylidenedioxy-6 α ,9 α -difluoro-11 β -hydroxy-3-oxo-androsta-1,4-diene-17 β -carbothioic acid S-methyl ester; methyl 9 α -chloro-6 α -fluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -propionyloxy-androsta-1,4-diene-17 α -carboxylate; 6 α ,9 α -difluoro-11 β -hydroxy-16 α -methyl-3-oxo-17 α -propionyloxy-androsta-1,4-diene-17 β -carbothioic acid S-(2-oxo-tetrahydrofuran-3-yl) ester; optionally in their pure isomeric forms (where such forms exist) and/or in the form of their pharmaceutically acceptable solvates, esters, acetals or salts, or where applicable solvates of any of these. Suitably, use is made of mometasone furoate, beclomethasone dipropionate or fluticasone propionate or glucocorticosteroids with an asymmetric acetal structure, e.g. comprising 16 α ,17 α -butylidenedioxy group, such as budesonide or rofleponide or pharmaceutically acceptable solvates, esters, acetals or salts, or where applicable, solvates thereof. The most preferred lipophilic glucocorticosteroid ester is rofleponide palmitate.

20

25

The amount of surfactant used in the composition should be less than 5 % (w/w) of the total composition weight. Preferably the amount of surfactant is less than 3 % (w/w) and most preferably less than 1 % (w/w) of the total composition weight. The concentration of the surfactant must, however, be higher than the critical micellar concentration (CMC), being the lowest concentration at which micelles are formed in an aqueous medium. The CMC value depends primarily upon the temperature and the concentration of possible additives. It lies within the competence of the skilled person to determine the CMC for each individual composition and thus prepare suitable micelles according to the present invention.

The amount of the glucocorticosteroid used depends on the field of use. If the glucocorticosteroid is used for treating diseases in the respiratory tract by inhalation a suitable daily dose is from 10 to 2400 µg, preferably from 10 to 1600 µg. If the glucocorticosteroid is used for treating intestinal diseases a suitable daily dose is from 400 to 4000 µg, preferably from 800 to 3000 µg.

The composition according to the invention may also contain one or more pharmaceutically acceptable additives such as buffers and other pH modifiers, antioxidants, complexing agents to further increase the stability, viscosity regulating agents and isotonicity modifying agents. Compounds used as such agents are compounds generally used in drug formulations e.g. EDTA for complexing and carboxymethyl cellulose (CMC) for regulating viscosity. As substances for adjusting the isotonicity can be mentioned glucose, mannitol, salts, glycerol and propylene-glycol. Preferably alkaline buffers are used such that the pH of the composition is from 4 to 7. It is, however, preferred to use one or more anti-oxidant(s), which may be water-soluble to a smaller or larger degree. Examples of such antioxidants include, without limitation, tocopherols, especially α-tocopherol, and preferably racemic α-tocopherol, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT) and ascorbic acid.

In order to prepare the aqueous composition according to the present invention the glucocorticosteroid drug has to be dissolved in a first step. It was found in the present invention that a stable composition of the glucocorticosteroid is obtained if the glucocorticosteroid is dissolved in the surfactant. Then the aqueous medium is added to the glucocorticosteroid-surfactant solution and the mixture is stirred, preferably intensely stirred, to obtain a stable and homogeneous solution. Preferably the aqueous medium is of the same temperature as the one of the glucocorticosteroid-surfactant solution before it is added to the solution. If other pharmaceutically acceptable additives are used they are suitably added to the aqueous medium before mixing with the glucocorticosteroid-surfactant solution if they are water soluble. Otherwise they are added to the surfactant solution. In a preferred embodiment of the process glucose is dissolved in the aqueous medium in an isotonic amount.

The surfactant used can be a solid compound at ambient temperature or a more or less fluid compound. If a solid surfactant is used it should be heated in order to melt it in a first step of the process. The glucocorticosteroid is then dissolved in the melted surfactant. This is a preferred embodiment of the invention.

If the surfactant is fluid enough the glucocorticosteroid can be dissolved directly in the surfactant at ambient temperature or it may be suitable to increase the temperature of the surfactant to more readily dissolve the glucocorticosteroid. Then the water is added.

A further possibility is to dissolve the surfactant in a conventional organic solvent, e.g. ethanol, and then to dissolve the glucocorticosteroid in this solution or vice versa. The organic solvent then has to be evaporated before the aqueous medium is added. It is important that the organic solvent is removed from the composition otherwise the composition will have a stinging effect in the nose of the patient if the composition is used for the manufacture of a medicament for treating allergic and/or inflammatory diseases in the respiratory tract.

Optionally the composition according to the invention can be made sterile in a conventional manner, e.g. by using dry heat, steam or irradiation.

The composition according to the invention is used for the manufacture of a medicament
5 for treating allergic and/or inflammatory diseases in the respiratory tract. The composition
can then be administered via the upper and lower respiratory tract, including nasal or oral
inhalation. The composition according to the invention can be used in common devices for
aqueous solutions for nasal and oral inhalation e.g. in a spray pump or in a nebulizer. For
administration by nebulisation reference is made to "Medication Nebulizer Performance",
10 Chest 110(2), (1996), pp. 498-505. The composition according to the invention is also used
for the manufacture of a medicament for treating intestinal diseases such as inflammatory
bowel diseases (IBD), ulcerative colitis and Crohn's disease. The compositions can then be
administered by rectal administration.

15 The invention also relates to a method for treatment of allergic and/or inflammatory
diseases in the respiratory tract of a mammal, including man. The composition according to
the invention is administered in a therapeutically effective amount to the mammal in need
of such a treatment, preferably by nasal or oral inhalation.

20 The invention also relates to a method of treatment of intestinal diseases in a mammal,
including man. The composition according to the invention is administered in a therapeu-
tically effective amount to the mammal in need of such a treatment, preferably by rectal
administration.

25 The invention will now be illustrated by the following non-limiting example:

EXAMPLE**Manufacturing of rofleponide palmitate in micellar solution.**

5 5 g Solutol® HS15 (polyethyleneglycol 660 12-hydroxystearate) manufactured by BASF of Germany is melted in a beaker at 35°C-40°C. 100 mg rofleponide palmitate is added to the melt and dissolved.

10 An isotonic solution of 25 g glucose in 495 g water is heated to 35-40°C and added to the melt using intense stirring. A clear solution containing 0.2 mg rofleponide palmitate/ml is obtained.

CLAIMS

1. A pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one
5 pharmaceutically acceptable surfactant.
2. The composition according to claim 1 or 2, wherein the surfactant is a non-ionic surfactant.
- 10 3. The composition according to claim 2, wherein said non-ionic surfactant is selected from the group consisting of poloxamers, polyoxyethylene alkyl ethers, polyoxyethylene stearates, polyoxyethyleneglycol hydroxystearates and polyoxyethylene sorbitan fatty acid esters.
- 15 4. The composition according to claim 3, wherein the non-ionic surfactant is a polyoxyethyleneglycol 12-hydroxystearate.
5. The composition according to claim 4, wherein the non-ionic surfactant is polyoxyethyleneglycol 660 12-hydroxystearate.
- 20 6. The composition according to claim 3, wherein the non-ionic surfactant is polysorbate 20, polysorbate 40, polysorbate 60 or polysorbate 80.
7. The composition according to any previous claim, wherein the glucocorticosteroid
25 is selected from the group consisting of mometasone furoate, beclomethasone dipropionate, fluticasone propionate, glucocorticosteroids with an asymmetric acetal structure involving a 16 α ,17 α -butylidenedioxy group, and pharmaceutically acceptable solvates, esters, acetals and salts, and solvates of any of these.

8. The composition according to claim 7, wherein the glucocorticosteroid is rofleponide palmitate.

9. A composition according to any previous claim, wherein the amount of the surfactant is less than 5 % (w/w) of the total composition weight, preferably less than 3 % (w/w), more preferably less than 1 % (w/w) of the total composition weight.

10. A composition according to any previous claim, wherein the composition further comprises one or more pharmaceutically acceptable additives selected from the group consisting of antioxidants, isotonicity modifying agents, pH modifiers, complexing agents and viscosity regulating agents.

11. A composition according to claim 10, wherein the isotonicity modifying agent is glucose.

12. A composition according to claim 10, wherein the antioxidant is selected from the group consisting of tocopherols, butylhydroxyanisole (BHA), butylhydroxytoluene (BHT) and ascorbic acid.

13. A process for the preparation of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant, the process comprising the steps of:

- a) dissolving the glucocorticosteroid in the surfactant; and
- b) adding the aqueous medium to the solution from step a) and stirring the solution.

14. The process according to claim 13, wherein the surfactant is a non-ionic surfactant.

15. The process according to claims 14, wherein said non-ionic surfactant is selected from the group consisting of poloxamers, polyoxyethylene alkyl ethers, polyoxyethylene-

stearates, polyoxyethyleneglycol hydroxystearates and polyoxyethylene sorbitan fatty acid esters.

16. The process according to claim 15, wherein the non-ionic surfactant is a polyoxy-
5 ethyleneglycol 12-hydroxystearate.

17. The process according to claim 16, wherein the non-ionic surfactant is polyoxy-
ethyleneglycol 660 12-hydroxystearate.

18. The process according to claim 15, wherein the polyoxyethylene sorbitan fatty acid
10 ester is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate
60 or polysorbate 80.

19. The process according to any one of claims 13-18, wherein the glucocorticosteroid
15 is selected from the group consisting of mometasone furoate, beclomethasone dipropionate,
fluticasone propionate, glucocorticosteroids with an asymmetric acetal structure involving
a 16 α ,17 α -butylidenedioxy group, and pharmaceutically acceptable solvates, esters, acetals
and salts, and solvates of any of these.

20. The process according to claim 19, wherein the glucocorticosteroid is rofleponide
20 palmitate.

21. The process according to any one of claims 13-20, wherein the amount of the
surfactant is less than 5 % (w/w) of the total composition weight, preferably less than 3 %
25 (w/w), more preferably less than 1 % (w/w) of the total composition weight.

22. The process according to any of the claims 13-21, wherein the composition further
comprises one or more pharmaceutically acceptable additives selected from the group
consisting of antioxidants, isotonicity modifying agents, pH modifiers, complexing agents
30 and viscosity regulating agents.

23. The process according to claim 22, comprising dissolving glucose in an isotonic amount in the aqueous medium before adding the aqueous medium to the solution from step a).

5

24. Use of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant, for the manufacture of a medicament for treating allergic and/or inflammatory diseases in the respiratory tract.

10

25. Use according to claim 24, wherein the daily dose of the glucocorticosteroid lies in the range of from 10 to 2400 μg , preferably from 10 to 1600 μg .

26. Use of a pharmaceutical composition comprising micelles in an aqueous medium, wherein the micelles comprise a lipophilic glucocorticosteroid and one and only one pharmaceutically acceptable surfactant, for the manufacture of a medicament for treating intestinal diseases.

15

27. Use according to claim 26, wherein the daily dose of the glucocorticosteroid lies in the range of from 400 to 4000 μg , preferably from 800 to 3000 μg .

20

28. Use according to any one of claims 24 to 27, wherein the composition is as defined in anyone of claims 2-12.

25

30